B-cell prolymphocytic leukemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(27 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{B-cell prolymphocytic leukemia}}
{{SI}}
{{SI}}
{{CMG}} {{CLG}}
{{CMG}}; {{AE}}{{Qurrat}}, {{CLG}}


{{SK}} B-PLL
{{SK}} B-PLL, Prolymphocytic leukemia, B-cell type


==Overview==
==[[B-cell prolymphocytic leukemia overview|Overview]]==
'''B-cell prolymphocytic leukemia''' is a more aggressive but still treatable form of [[leukemia]]. The malignant [[B cells]] are larger than average.


==Pathophysiology==
==[[B-cell prolymphocytic leukemia historical perspective|Historical Perspective]]==
It is postulated that the originating cell line for this disease is a mature B-cell. Due to the systemic nature of this disease, leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, skin.


===Genetics===
==[[B-cell prolymphocytic leukemia classification|Classification]]==
It can involve deletions from [[chromosome 11]] and [[chromosome 13]].<ref name="pmid10720137">{{cite journal |author=Lens D, Matutes E, Catovsky D, Coignet LJ |title=Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL) |journal=Leukemia |volume=14 |issue=3 |pages=427-30 |year=2000 |pmid=10720137 |doi=}}</ref>


===Markers===
==[[B-cell prolymphocytic leukemia pathophysiology|Pathophysiology]]==
*A case has been described as [[CD20]]+, [[CD22]]+, and [[CD5 (protein)|CD5]]-.<ref name="pmid9657013">{{cite journal |author=Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H |title=Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not? |journal=Jpn. J. Clin. Oncol. |volume=28 |issue=4 |pages=267–9 |date=April 1998 |pmid=9657013 |doi= 10.1093/jjco/28.4.267|url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9657013}}</ref>
*It can also be CD5+.<ref name="urlPathology">{{cite web |url=http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm |title=Pathology |format= |work= |accessdate=2009-01-31| archiveurl= http://web.archive.org/web/20090207235133/http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm| archivedate= 7 February 2009 <!--DASHBot-->| deadurl= no}}</ref>
*Another case was described as [[CD45]]+, [[CD19]]+, [[CD20]]+, [[CD5]]+, [[HLA-DR]]+, [[CD10]]-, [[CD23]]+/-, [[CD38]]+ and [[FMC7]]-.<ref name="pmid16997373">{{cite journal |author=Crisostomo RH, Fernandez JA, Caceres W |title=Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia |journal=Leuk. Res. |volume=31 |issue=5 |pages=699–701 |date=May 2007 |pmid=16997373 |doi=10.1016/j.leukres.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00218-9}}</ref>


==Prognosis==
==[[B-cell prolymphocytic leukemia causes|Causes]]==
It has a relatively poor prognosis.<ref name="pmid16642047">{{cite journal |author=Del Giudice I, Davis Z, Matutes E, ''et al'' |title=IgVH genes mutation and usage, [[ZAP-70]] and [[CD38]] expression provide new insights on B-cell prolymphocytic leukemia (B-PLL) |journal=Leukemia |volume=20 |issue=7 |pages=1231-7 |year=2006 |pmid=16642047 |doi=10.1038/sj.leu.2404238}}</ref>. But usually has a better prognosis than T-cell prolymphocytic leukemia.


==Differential Diagnosis==
==[[B-cell prolymphocytic leukemia differential diagnosis|Differentiating B-cell prolymphocytic leukemia from other Diseases]]==
* Hairy cell leukemia<ref name="pmid19110524">{{cite journal |author=Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S |title=Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia |journal=Rinsho Ketsueki |volume=49 |issue=12 |pages=1619–22 |date=December 2008 |pmid=19110524 |doi=10.11406/rinketsu.49.1619}}</ref>
 
* Waldenström macroglobulinemia<ref name="pmid19110524">{{cite journal |author=Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S |title=Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia |journal=Rinsho Ketsueki |volume=49 |issue=12 |pages=1619–22 |date=December 2008 |pmid=19110524 |doi=10.11406/rinketsu.49.1619}}</ref>
==[[B-cell prolymphocytic leukemia epidemiology and demographics|Epidemiology and Demographics]]==
 
==[[B-cell prolymphocytic leukemia risk factors|Risk Factors]]==
 
==[[B-cell prolymphocytic leukemia screening|Screening]]==
 
==[[B-cell prolymphocytic leukemia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
 
==Diagnosis==
 
[[B-cell prolymphocytic leukemia history and symptoms|History and Symptoms ]] | [[ B-cell prolymphocytic leukemia physical examination|Physical Examination]] | [[B-cell prolymphocytic leukemia laboratory findings|Laboratory Findings]] | [[ B-cell prolymphocytic leukemia biopsy|Biopsy]] | [[B-cell prolymphocytic leukemia CT|CT ]] | [[B-cell prolymphocytic leukemia MRI|MRI]] | [[B-cell prolymphocytic leukemia other imaging findings|Other Imaging Findings]] | [[B-cell prolymphocytic leukemia other diagnostic studies|Other Diagnostic Studies]]


==Treatment==
==Treatment==
*Splenic irradiation has been used in the treatment.<ref name="pmid19110524">{{cite journal |author=Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S |title=Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia |journal=Rinsho Ketsueki |volume=49 |issue=12 |pages=1619–22 |date=December 2008 |pmid=19110524 |doi=10.11406/rinketsu.49.1619}}</ref>
[[B-cell prolymphocytic leukemia medical therapy|Medical Therapy]] | [[B-cell prolymphocytic leukemia surgery|Surgery]] | [[B-cell prolymphocytic leukemia primary prevention|Primary Prevention]] | [[B-cell prolymphocytic leukemia secondary prevention|Secondary Prevention]] | [[B-cell prolymphocytic leukemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[B-cell prolymphocytic leukemia future or investigational therapies|Future or Investigational Therapies]]
*Cladribine (2-chlorodeoxyadenosine) appears to be an active agent (60% complete remission rate) for patients with de novo B-cell prolymphocytic leukemia.<ref name=B-CellPLl>{{cite web | title = National Cancer Institute| url =http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq}}</ref>


==References==
==References==

Latest revision as of 16:33, 1 April 2019

B-cell prolymphocytic leukemia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell prolymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell prolymphocytic leukemia On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell prolymphocytic leukemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell prolymphocytic leukemia

CDC on B-cell prolymphocytic leukemia

B-cell prolymphocytic leukemia in the news

Blogs on B-cell prolymphocytic leukemia

Directions to Hospitals Treating B-cell prolymphocytic leukemia

Risk calculators and risk factors for B-cell prolymphocytic leukemia

WikiDoc Resources for B-cell prolymphocytic leukemia

Articles

Most recent articles on B-cell prolymphocytic leukemia

Most cited articles on B-cell prolymphocytic leukemia

Review articles on B-cell prolymphocytic leukemia

Articles on B-cell prolymphocytic leukemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on B-cell prolymphocytic leukemia

Images of B-cell prolymphocytic leukemia

Photos of B-cell prolymphocytic leukemia

Podcasts & MP3s on B-cell prolymphocytic leukemia

Videos on B-cell prolymphocytic leukemia

Evidence Based Medicine

Cochrane Collaboration on B-cell prolymphocytic leukemia

Bandolier on B-cell prolymphocytic leukemia

TRIP on B-cell prolymphocytic leukemia

Clinical Trials

Ongoing Trials on B-cell prolymphocytic leukemia at Clinical Trials.gov

Trial results on B-cell prolymphocytic leukemia

Clinical Trials on B-cell prolymphocytic leukemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on B-cell prolymphocytic leukemia

NICE Guidance on B-cell prolymphocytic leukemia

NHS PRODIGY Guidance

FDA on B-cell prolymphocytic leukemia

CDC on B-cell prolymphocytic leukemia

Books

Books on B-cell prolymphocytic leukemia

News

B-cell prolymphocytic leukemia in the news

Be alerted to news on B-cell prolymphocytic leukemia

News trends on B-cell prolymphocytic leukemia

Commentary

Blogs on B-cell prolymphocytic leukemia

Definitions

Definitions of B-cell prolymphocytic leukemia

Patient Resources / Community

Patient resources on B-cell prolymphocytic leukemia

Discussion groups on B-cell prolymphocytic leukemia

Patient Handouts on B-cell prolymphocytic leukemia

Directions to Hospitals Treating B-cell prolymphocytic leukemia

Risk calculators and risk factors for B-cell prolymphocytic leukemia

Healthcare Provider Resources

Symptoms of B-cell prolymphocytic leukemia

Causes & Risk Factors for B-cell prolymphocytic leukemia

Diagnostic studies for B-cell prolymphocytic leukemia

Treatment of B-cell prolymphocytic leukemia

Continuing Medical Education (CME)

CME Programs on B-cell prolymphocytic leukemia

International

B-cell prolymphocytic leukemia en Espanol

B-cell prolymphocytic leukemia en Francais

Business

B-cell prolymphocytic leukemia in the Marketplace

Patents on B-cell prolymphocytic leukemia

Experimental / Informatics

List of terms related to B-cell prolymphocytic leukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Carlos A Lopez, M.D. [3]

Synonyms and keywords: B-PLL, Prolymphocytic leukemia, B-cell type

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell prolymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Biopsy | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

References

Template:Jb1


Template:WikiDoc Sources